EN DE
Watch Oncoclinicas do Brasil for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Oncoclinicas do Brasil (ONCO3) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Oncoclinicas do Brasil stock BRL 0.27, price BRL 0.98, that is 72.4% below the price, quality 28 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare BR · ISIN BRONCOACNOR6

OD Oncoclinicas do Brasil logo Thin data Nov 8, 2026

Oncoclinicas do Brasil

ONCO3 · SA
Very expensive, weak quality

Our calculation puts a fair price 72% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +23.0 %/yr in BRL)
Revenue last quarter 29% below a year ago.
Fair value R$0.2700 · Strongly overvalued
Quality 28/100
Loss-making · -84.8% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 8/100 · thin data
Thin data
Watch Oncoclinicas do Brasil for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$19.24 R$0.5500 Fair Value R$0.2700 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range R$0.5500 – R$19.24 · fair‑value band R$0.1800 – R$0.3200 · the R$0.9800 price screens above the R$0.2700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Oncoclinicas do Brasil in your weekly email

Every Wednesday you see whether Oncoclinicas do Brasil is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America.

Show moreShow less

The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, chemotherapy, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stomach, bladder cancer, oncological, kidney cancer, gynecological, and testicular cancer.

It also provides diagnostics services comprising pathological analysis, genetic testing, molecular journey, personalized medicine and individualized treatment, myelogram-bone marrow biopsy, and ONCO test-PDO. In addition, the company offers treatment support services, which include veinviewer, cryotherapy, integrative medicine, and DeLife, as well as hilotherapy, laser therapy, OC care line, OC precision medicine, OncoACCESS, survivorship, and telemedicine services.

Oncoclínicas do Brasil Serviços Médicos S.A. was founded in 2010 and is headquartered in São Paulo, Brazil.

Stock analysis

Oncoclinicas do Brasil (ONCO3) currently trades at R$0.9800, while our model-based Fair Value estimate is R$0.2700, 72% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 93/100, which puts the data coverage at low.

Scenario range: R$0.1800 (bear) to R$0.3200 (bull), the price of R$0.9800 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Oncoclinicas do Brasil reported revenue of R$5.7B in FY2025 versus R$2.7B in FY2021, a compound +20.7%/yr. Reported net income was −R$3.6B in FY2025.

Key figures

Market cap R$1.1B (≈ $197M) Micro · P/S ratio 0.16 · EPS (TTM) R$−5.13 · Dividend yield 4.6% · Net margin −84.8% · Return on equity −274% · Return on assets (EBIT) −3.7% (5-year average) · Operating margin −27.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 67% below its 52-week high and 78% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −72%, ONCO3 screens richer than that median.

Fair Value models

Bear R$0.1800 Fair Value R$0.2700 Bull R$0.3200
Price R$0.9800 · Downside -72.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Gordon GGM R$0.1800 R$0.2700 R$0.3200 69
DDM Multi-Stage R$0.1800 R$0.2700 R$0.2900 67
All 2 models by family
Dividend Discount
Gordon GGM R$0.1800 R$0.2700 R$0.3200 69
DDM Multi-Stage R$0.1800 R$0.2700 R$0.2900 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 26
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 7
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 24
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 55
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.0%
Start year 2020 (pandemic). Over 10 years: +28.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.6% (2020) → −43.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ONCO3 screens overvalued: fair value 72% below the price. Compare with HCA Healthcare, Inc →

Compare Oncoclinicas do Brasil with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −72.4% · Bottom 25%
Profitability
Return on assets −50.8% · Bottom 25%
Net margin (12 months) −84.8% · Bottom 25%
Operating margin (12 months) −27.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −28.5% · Bottom 25%
Dividend yield (12 months) 4.6% · Top 25%
Balance sheet
Debt / equity 0.12× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 1.21× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.22× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 32
HEALTH (low debt)94 · sector 90
DIVIDEND (yield)92 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs ONCO3
Aier Eye Hospital Group 300015 ¥9.01 ¥10.88 +21% vs ONCO3
DaVita Inc DVA $191.35 $218.90 +14% vs ONCO3
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs ONCO3
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs ONCO3
The Ensign Group ENSG $181.08 $140.09 −23% vs ONCO3
Encompass Health Corporation EHC $137.54 $94.81 −31% vs ONCO3
Fresenius SE FRE €52.48 €34.77 −34% vs ONCO3
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,446 ₹5,234 −38% vs ONCO3
Dr. Sulaiman Al Habib Medical Services Group 4013 215.00 SAR 109.45 SAR −49% vs ONCO3

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oncoclinicas do Brasil: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Oncoclinicas do Brasil Fair Value". https://www.fairvalue-calculator.com/stock/ONCO3

Frequently asked questions

Is Oncoclinicas do Brasil (ONCO3) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of R$0.2700 versus a price of R$0.9800, about 72% lower (overvalued).
What is the fair value of ONCO3?
Our model-based fair value for Oncoclinicas do Brasil is R$0.2700 (as of Nov 8, 2026), built from audited fundamentals. The current price: R$0.9800.
What is the quality score of ONCO3?
Oncoclinicas do Brasil has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oncoclinicas do Brasil (ONCO3)?
Our model-based price target is the fair value of R$0.2700 (as of Nov 8, 2026) from 2 valuation models. Cautious scenario R$0.1800, optimistic scenario R$0.3200. It is a calculation from audited fundamentals, not an analyst target.
What is the Oncoclinicas do Brasil stock forecast for 2026?
Our models put fair value at R$0.2700, about 72% lower versus a price of R$0.9800 (overvalued). Cautious scenario R$0.1800, optimistic scenario R$0.3200. The calculation is refreshed regularly with new filings.
What is the revenue of Oncoclinicas do Brasil (ONCO3)?
Oncoclinicas do Brasil reported trailing-twelve-month revenue of about R$5.0B (latest available figure, as of Nov 8, 2026).
Does Oncoclinicas do Brasil pay a dividend?
Oncoclinicas do Brasil currently shows a dividend yield of 4.60% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Oncoclinicas do Brasil (ONCO3)?
Oncoclinicas do Brasil has a dividend yield of 4.6%.
What is the intrinsic value of Oncoclinicas do Brasil (ONCO3)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oncoclinicas do Brasil it is R$0.2700 per share (as of Nov 8, 2026), against a price of R$0.9800. It is the blended result of 2 valuation models in 1 family (Dividend Discount).
Is Oncoclinicas do Brasil stock overvalued or undervalued in 2026?
As of Nov 8, 2026, ONCO3 trades above its calculated fair value: price R$0.9800, fair value R$0.2700, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONCO3?
No. The price is what the market pays today (R$0.9800); the fair value is what the company's own numbers justify (R$0.2700). For Oncoclinicas do Brasil the two are R$0.7100 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oncoclinicas do Brasil worth?
The market values Oncoclinicas do Brasil at about R$1.1B (market capitalisation, as of Nov 8, 2026). Per share that is R$0.9800; our models calculate a fair value of R$0.2700 per share.
What do the bullish and bearish scenarios say about ONCO3?
Our models span a range for Oncoclinicas do Brasil: cautious scenario R$0.1800, base R$0.2700, optimistic R$0.3200 per share (as of Nov 8, 2026, price R$0.9800). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oncoclinicas do Brasil (ONCO3)?
Balance-sheet figures for Oncoclinicas do Brasil (as of Nov 8, 2026): return on equity −273.5%, debt of 0.12 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is ONCO3 from its 52-week high?
Oncoclinicas do Brasil trades at R$0.9800, about 67% below its 52-week high of R$3.00 and 78% above the low of R$0.5500 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of R$0.2700 is for.
Which stocks are comparable to Oncoclinicas do Brasil?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oncoclinicas do Brasil stock attractive at the current price?
The data as of Nov 8, 2026: price R$0.9800, calculated fair value R$0.2700 (−72%), Quality Score 28/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONCO3 calculated?
We run Oncoclinicas do Brasil through 2 models from 1 family: Dividend Discount. Every model gets the same audited fundamentals; the fair value of R$0.2700 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Oncoclinicas do Brasil itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oncoclinicas do Brasil (ONCO3)?
The closing price on Nov 6, 2026 was R$0.9800. Our model-based fair value is R$0.2700, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oncoclinicas do Brasil right now?
The price sits above even our optimistic bull case (R$0.3200). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Oncoclinicas do Brasil

How large is the market capitalisation of Oncoclinicas do Brasil (ONCO3)?
The market capitalisation of Oncoclinicas do Brasil is R$1.1B (≈ $197M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oncoclinicas do Brasil (ONCO3)?
The price-to-sales ratio of Oncoclinicas do Brasil is 0.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oncoclinicas do Brasil (ONCO3)?
Earnings per share at Oncoclinicas do Brasil are R$−5.13. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Oncoclinicas do Brasil (ONCO3)?
The dividend yield of Oncoclinicas do Brasil is 4.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Oncoclinicas do Brasil (ONCO3)?
The net margin of Oncoclinicas do Brasil is −84.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oncoclinicas do Brasil (ONCO3)?
The return on equity (ROE) of Oncoclinicas do Brasil is −274% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oncoclinicas do Brasil (ONCO3)?
On an EBIT basis the return on assets of Oncoclinicas do Brasil is −3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oncoclinicas do Brasil (ONCO3)?
The operating margin of Oncoclinicas do Brasil is −27.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oncoclinicas do Brasil (ONCO3)?
Revenue at Oncoclinicas do Brasil is growing −28.5% versus a year earlier (3y avg +12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oncoclinicas do Brasil (ONCO3)?
Earnings per share at Oncoclinicas do Brasil are growing −85.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Oncoclinicas do Brasil (ONCO3) generate?
The free cash flow of Oncoclinicas do Brasil is −R$287M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Oncoclinicas do Brasil (ONCO3) carry?
The net debt of Oncoclinicas do Brasil is R$3.3B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Oncoclinicas do Brasil in the live analysis

One click puts Oncoclinicas do Brasil on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.